Daubaraitė Aurelija, Marinskis Germanas, Račkauskas Gediminas
Faculty of Medicine, Vilnius University, Vilnius, Lithuania.
Centre of Cardiology and Angiology, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania.
Postepy Kardiol Interwencyjnej. 2023 Jun;19(2):99-112. doi: 10.5114/aic.2023.129207. Epub 2023 Jun 30.
The objective of the study is to systematically evaluate the safety and efficacy of peri-procedural utilization of anticoagulation therapy during cardiovascular implantable electronic device procedures.
The review materials were based on comprehensive retrieval of randomized controlled trials and observational studies published until April 2023. Studies which compared different management strategies of long-term anticoagulation therapy during peri-procedural cardiac rhythm device implantation and compared the complications of bleeding and/or thromboembolic events were selected and reviewed.
Studies analysing non-vitamin K oral anticoagulants interruption versus continuation during peri-procedural implantable cardiac device surgery found no statistically significant difference in bleeding or thromboembolic complications between these strategies. Studies comparing non-vitamin K oral anticoagulants with vitamin K antagonists also showed no statistically significant difference. One study comparing uninterrupted warfarin with interrupted warfarin with heparin bridging reported a reduced incidence of clinically significant device pocket haematoma in patients with continued warfarin treatment (relative risk = 0.19; 95% confidence interval: 0.10 to 0.36; < 0.001). A sub-analysis of one study comparing dabigatran versus warfarin with heparin bridging and without bridging reported a lower risk of pocket haematoma with dabigatran when compared to warfarin with heparin bridging (risk difference: -8.62%, 95% confidence interval: -24.15 to -0.51%; = 0.034). Both bleeding and thromboembolic complications were rare.
The traditional method of vitamin K antagonists interruption with heparin bridging is less safe than continuing vitamin K antagonists at therapeutic levels. Both continuation and interruption strategies of non-vitamin K anticoagulants during cardiac device surgery seem to be safe and appropriate.
本研究的目的是系统评价心血管植入式电子设备手术期间围手术期使用抗凝治疗的安全性和有效性。
综述材料基于对截至2023年4月发表的随机对照试验和观察性研究的全面检索。选择并综述了比较围手术期心律装置植入期间长期抗凝治疗不同管理策略以及比较出血和/或血栓栓塞事件并发症的研究。
分析围手术期植入式心脏设备手术期间非维生素K口服抗凝剂中断与继续使用的研究发现,这些策略在出血或血栓栓塞并发症方面无统计学显著差异。比较非维生素K口服抗凝剂与维生素K拮抗剂的研究也未显示出统计学显著差异。一项比较不间断华法林与中断华法林加肝素桥接的研究报告称,持续使用华法林治疗的患者临床显著的设备囊袋血肿发生率降低(相对风险=0.19;95%置信区间:0.10至0.36;<0.001)。一项比较达比加群与华法林加肝素桥接和不加桥接的研究的亚分析报告称,与华法林加肝素桥接相比,达比加群导致囊袋血肿的风险更低(风险差异:-8.62%,95%置信区间:-24.15至-0.51%;=0.034)。出血和血栓栓塞并发症均很少见。
维生素K拮抗剂中断加肝素桥接的传统方法不如在治疗水平上继续使用维生素K拮抗剂安全。心脏设备手术期间非维生素K抗凝剂的继续使用和中断策略似乎都是安全且合适的。